Australia is currently facing a “critical” and escalating shortage of several key medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD), sparking widespread anxiety and disruption for patients, families, and doctors across the country.
The shortage, primarily impacting immediate-release and long-acting formulations of the stimulant medication methylphenidate (commonly sold as Ritalin or Concerta), has been attributed to a combination of global supply chain issues and unprecedented growth in ADHD diagnoses. The issue has been exacerbated by the recent relaxation of prescribing rules in several states, which has increased the demand for these drugs.
Patient Impact and Advocacy Response
The Therapeutic Goods Administration (TGA) has acknowledged the severity of the crisis, releasing multiple notices about the shortages and estimating that normal supply levels may not return until early 2026 for some brands. For patients, the shortage means:
Disruptions to Care: Many patients are forced to switch between different dosages, brands, or even medication classes, often requiring new consultations with psychiatrists or specialized GPs.
Emotional Distress: Advocacy groups report significant distress, as inconsistent access to medication impacts work, study, and daily functioning.
The ADHD community is urging the TGA to explore more aggressive strategies, including fast-tracking approvals for international equivalent products and improving communication with pharmacies to prevent patients from repeatedly visiting stores only to find empty shelves.